Stay updated on Filgotinib and Lanraplenib in Female CLE Clinical Trial
Sign up to get notified when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.

Latest updates to the Filgotinib and Lanraplenib in Female CLE Clinical Trial page
- Check6 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.2%
- Check13 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, while several terms related to diseases and previous location details have been removed.SummaryDifference2%
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check34 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check41 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference1%
- Check49 days agoChange DetectedThe web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.SummaryDifference0.2%
Stay in the know with updates to Filgotinib and Lanraplenib in Female CLE Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.